当前位置:首页 >财报库 > 报告详情

默沙东Merck & Co. Inc.(MRK)2025年第三季度财报电话会纪要「NYSE」(英文版)(17页).pdf

上传人: 1****1 编号:987240 2025-12-09 17页 172.91KB

下载:

1、REFINITIV STREETEVENTSEDITED TRANSCRIPTMRK.N-Q3 2025 Merck&Co Inc Earnings CallEVENT DATE/TIME:OCTOBER 30,2025/1:00PM GMTOVERVIEW:Company SummaryREFINITIV STREETEVENTS|Contact Us2025 Refinitiv.All rights reserved.Republication or redistribution of Refinitiv content,including by framing or similar me

2、ans,is prohibited without the prior writtenconsent of Refinitiv.Refinitiv and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.CORPORATE PARTICIPANTSPeter Dannenbaum Merck&Co Inc-Senior Vice President,Investor RelationsRobert Davis Merck&Co Inc-Chairman of the B

3、oard,President,Chief Executive OfficerCaroline Litchfield Merck&Co Inc-Chief Financial Officer,Executive Vice PresidentDean Li Merck&Co Inc-Executive Vice President,President-Merck Research LaboratoriesCONFERENCE CALL PARTICIPANTSAsad Haider Goldman Sachs Group Inc-AnalystGeoff Meacham Citi-AnalystA

4、kash Tewari Jefferies LLC-AnalystEvan Seigerman Bank of Montreal-AnalystDaina Graybosch Leerink Partners LLC-AnalystChristopher Schott JPMorgan Chase&Co-AnalystCarter Gould Cantor Fitzgerald LP-AnalystTerence Flynn Morgan Stanley&Co Ltd-AnalystUmer Raffat Evercore Inc-Equity AnalystCourtney Breen Sa

5、nford C Bernstein&Co LLC-Equity AnalystVamil Divan Guggenheim Securities LLC-Equity AnalystLuisa Hector Joh Berenberg Gossler&Co KG-Equity AnalystAlexandria Hammond Wolfe Research LLC-Equity AnalystPRESENTATIONOperatorWelcome to the Merck&Co,Inc.Rahway,New Jersey,USA third quarter sales and earnings

6、 conference call.(Operator Instructions)This call is beingrecorded.If you have any objections,you may disconnect at this time.I would now like to turn the call over to Mr.Peter Dannenbaum,Senior Vice President,Investor Relations.Sir,you may begin.Peter Dannenbaum-Merck&Co Inc-Senior Vice President,I

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
- **业绩概述**:Merck & Co Inc 在2025年第三季度实现了稳健的业绩,收入增长4%,达到173亿美元。 - **产品销售**:KEYTRUDA 销售增长8%,达到81亿美元,主要得益于晚期癌症和早期癌症的强劲需求。WINREVAIR 销售达到3.6亿美元,CAPVAXIVE 销售达到2.44亿美元。 - **研发进展**:正在进行约80项3期临床试验,涵盖多个治疗领域,包括心血管、免疫学、HIV、眼科和肿瘤学。 - **战略收购**:完成了对Verona Pharma的战略收购,为未来十年提供了另一个重要的增长驱动因素。 - **未来展望**:预计2025年全年收入在645亿美元至655亿美元之间,每股收益在8.93美元至8.98美元之间。
业绩亮眼,管线强劲" ** "Merck如何凭借其创新药物和疫苗组合,在第三季度实现强劲增长?" 哪些项目将引领未来增长?" ** "Merck的哪些新药项目有望在未来几年内成为公司的增长引擎?"
客服
商务合作
小程序
服务号
折叠